Official publication of Rawalpindi Medical University
Impact of Comorbidities on the Severity of Disease & Outcome in Children with COVID 19 at a Tertiary Care Pediatric Hospital, Rawalpindi.

Supplementary Files


How to Cite

Asghar RM, Sharif M, Saheel K, Khan I, Hussain A, Ashraf RR. Impact of Comorbidities on the Severity of Disease & Outcome in Children with COVID 19 at a Tertiary Care Pediatric Hospital, Rawalpindi. JRMC [Internet]. 2023 Jun. 24 [cited 2024 Apr. 23];27(2). Available from:


Introduction: Coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was initially identified in Wuhan, China, in December 2019. The virus affects almost all countries of the world. It has infected humans in all age groups, of all ethnicities, both males and females. It is considered that COVID-19, in those with underlying health conditions or co-morbidities, has an increasingly rapid and severe progression, often leading to death. This study is designed to evaluate the impact of co-morbidities on the severity and outcome of COVID-19 infection in children.

Methods: This retrospective observational study was conducted at the pediatric department, Benazir Bhutto Hospital Rawalpindi from March 2020 to September 2021. Every confirmed COVID-19 admitted case according to inclusion criteria was enrolled for the study. Data were retrieved from hospital records; data was recorded on a predesigned study questionnaire, entered and analyzed in SPSS version 24 for descriptive statistics and bivariate analysis.

Results: 109 children were enrolled with confirmed COVID-19, of these 64(58.7%) were males and 45(41.2%) were females. The age of the patients ranged from infants to 12 years with a mean age of 27.25 months. Comorbidities were present in 70 patients     (64.2%).CHD was the most common co-morbid condition (n=18, 16.5%). Most of the patients experienced mild to moderate symptoms (n=64.2%) while severe symptoms were found in (n=35.8%) patients. 27 patients (24.8%) required Ventilatory support, and of these 20 patients (18.3%) had underlying co-morbidity. The total number of patients who expired was 27(24.7%), and 30.3% of patients who expired had co-morbid conditions. the patients with co-morbid conditions had a longer stay in the hospital. 35 patients (32.1%)with underlying co-morbidity remained admitted for more than a week and 13 patients(9%)for more than two weeks.

Conclusion: Pediatric patients with co-morbidities have a higher risk of severe COVID-19 and associated mortality than children without underlying disease. Children with underlying conditions need to be carefully assessed and closely monitored. Further data are required to define these associations and adequate guidelines to manage high-risk children with COVID-19.

Keywords: Coronavirus, COVID-19, Pediatrics, Co-morbidity, Severity, Outcome


Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020 Nov 1;52(11):549-557. 10.1152/physiolgenomics.00089.2020. Epub 2020 Sep 29. PMID: 32991251; PMCID: PMC7686876.

Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, Khan ST. COVID-19: A Global Challenge with Old History, Epidemiology, and Progress So Far. Molecules. 2020 Dec 23;26(1):39. doi: 10.3390/molecules26010039. PMID: 33374759; PMCID: PMC7795815.

Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J MicrobiolImmunol Infect. 2021 Apr;54(2):159-163. doi: 10.1016/j.jmii.2020.03.022. Epub 2020 Mar 31. PMID: 32265180; PMCID: PMC7138183.

Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Dittrich S, Domen J, Horn SRA, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020 Jul 7;7(7): CD013665. doi: 10.1002/14651858.CD013665. Update in: Cochrane Database Syst Rev. 2021 Feb 23;2:CD013665. PMID: 32633856; PMCID: PMC7386785.

CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426. doi: 10.15585/mmwr.mm6914e4. PMID: 32271728; PMCID: PMC7147903.

Williams PCM, Howard-Jones AR, Hsu P, Palasanthiran P, Gray PE, McMullan BJ, Britton PN, Bartlett AW. SARS-CoV-2 in children: spectrum of disease, transmission, and immunopathological underpinnings. Pathology. 2020 Dec;52(7):801-808. doi: 10.1016/j.pathol.2020.08.001. Epub 2020 Aug 19. PMID: 32888706; PMCID: PMC7437539.

Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z, Younas S. COVID-19, and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020 Dec;13(12):1833-1839. doi: 10.1016/j.jiph.2020.07.014. Epub 2020 Aug 4. PMID: 32788073; PMCID: PMC7402107.

Tsankov BK, Allaire JM, Irvine MA, Lopez AA, Sauvé LJ, Vallance BA, Jacobson K. Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis. Int J Infect Dis. 2021 Feb;103:246-256. doi: 10.1016/j.ijid.2020.11.163. Epub 2020 Nov 20. PMID: 33227520; PMCID: PMC7679116.

Rao S, Gavali V, Prabhu S, et al. Outcome of children admitted with SARS-CoV-2 infection: Experiences from a pediatric public hospital. Indian Pediatr. 2021;58:358-62.

Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. International Journal of Infectious Diseases. 2020 Jul 25.

Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547

Cheng S, Zhao Y, Wang F, Chen Y, Kaminga AC, Xu H. Comorbidities’ potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis. Medicine. 2021 Mar 26;100(12):e24971.

Kapoor D, Kumar V, Pemde H, Singh P. Impact of Comorbidities on Outcome in Children With COVID-19 at a Tertiary Care Pediatric Hospital. Indian Pediatr. 2021 Jun 15;58(6):572-575. doi: 10.1007/s13312-021-2244-0. PMID: 34176797; PMCID: PMC8253676.

Shaikh FS, Aldhafferi N, Buker A, et al. Comorbidities and Risk Factors for Severe Outcomes in COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study. J MultidiscipHealthc. 2021;14:2169-2183

Williams N, Radia T, Harman K, Agrawal P, Cook J, Gupta A. COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. European Journal of Pediatrics. 2021 Mar;180(3):689-97.

Prata-Barbosa A, Lima-Setta F, Santos GR, Lanziotti VS, Castro RE, Souza DC, Raymundo CE, Oliveira FR, Lima LF, Tonial CT, Colleti J. Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study☆,☆☆. Jornal de pediatria. 2020 Nov 11;96:582-92.

Aimen C. Bari A. Rashid J, et al.Comorbidity and covid-19 in children-a single-center experience. Pakistan Paediatric Journal; 44(4):306-313, 2020.

Mania A, Pokorska-Śpiewak M, Figlerowicz M, Pawłowska M, Mazur-Melewska K, Faltin K, et al. Pneumonia, gastrointestinal symptoms, comorbidities, and coinfections as factors related to a lengthier hospital stay in children with COVID-19—analysis of a paediatric part of Polish register SARSTer. Infect Dis (Auckl) [Internet]. 2022;54(3):196–204. Available from:

Tsankov BK, Allaire JM, Irvine MA, Lopez AA, Sauvé LJ, Vallance BA, Jacobson K. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2021 Feb 1;103:246-56

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright (c) 2023 Abid Hussain